State Street
TARA icon

State Street’s Protara Therapeutics TARA Stock Holding History

State Street’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.08M Buy
1,068,295
+63,153
+6% +$300K ﹤0.01% 3104
2026
Q1 		$5.24M Buy
1,005,142
+434,264
+76% +$2.57M ﹤0.01% 2938
2025
Q4 		$3.04M Buy
570,878
+220,787
+63% +$1.23M ﹤0.01% 3199
2025
Q3 		$1.52M Buy
350,091
+59,184
+20% +$192K ﹤0.01% 3421
2025
Q2 		$881K Buy
290,907
+207,707
+250% +$716K ﹤0.01% 3512
2025
Q1 		$354K Buy
83,200
+1,000
+1% +$4.47K ﹤0.01% 3683
2024
Q4 		$434K Buy
82,200
+55,600
+209% +$180K ﹤0.01% 3653
2024
Q3 		$48.7K Hold
26,600
– – ﹤0.01% 4108
2024
Q2 		$55.3K Hold
26,600
– – ﹤0.01% 4125
2024
Q1 		$107K Sell
26,600
-4,300
-14% -$13.9K ﹤0.01% 4021
2023
Q4 		$57.8K Hold
30,900
– – ﹤0.01% 4172
2023
Q3 		$51.6K Hold
30,900
– – ﹤0.01% 4281
2023
Q2 		$73.9K Hold
30,900
– – ﹤0.01% 4303
2023
Q1 		$95.8K Hold
30,900
– – ﹤0.01% 4338
2022
Q4 		$82.8K Hold
30,900
– – ﹤0.01% 4427
2022
Q3 		$91K Hold
30,900
– – ﹤0.01% 4495
2022
Q2 		$91K Hold
30,900
– – ﹤0.01% 4565
2022
Q1 		$158K Buy
30,900
+1,100
+4% +$5.78K ﹤0.01% 4471
2021
Q4 		$201K Buy
29,800
+7,000
+31% +$48.3K ﹤0.01% 4351
2021
Q3 		$158K Buy
22,800
+12,441
+120% +$97K ﹤0.01% 4431
2021
Q2 		$101K Sell
10,359
-49,774
-83% -$564K ﹤0.01% 4365
2021
Q1 		$946K Buy
60,133
+10,100
+20% +$187K ﹤0.01% 3632
2020
Q4 		$1.21M Buy
50,033
+27,015
+117% +$582K ﹤0.01% 3526
2020
Q3 		$387K Buy
23,018
+4,861
+27% +$113K ﹤0.01% 3599
2020
Q2 		$532K Buy
+18,157
New +$562K ﹤0.01% 3535
2016
Q2 		– Sell
-2,361
Closed -$729K – 3762
2016
Q1 		$729K Buy
2,361
+874
+59% +$282K ﹤0.01% 3285
2015
Q4 		$924K Buy
1,487
+123
+9% +$72.2K ﹤0.01% 3223
2015
Q3 		$758K Buy
1,364
+183
+15% +$113K ﹤0.01% 3260
2015
Q2 		$844K Buy
+1,181
New +$731K ﹤0.01% 3280

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

State Street's TARA Position: Q2 2026 in Review

State Street increased its Protara Therapeutics (TARA) stake by 6.3% in Q2 2026, buying an estimated $300K and bringing the position to 1,068,295 shares worth $4.08M. The position accounts for ﹤0.01% of the portfolio, ranked #3104.

State Street first reported a position in TARA in Q2 2015 and has held it in 29 quarters since. The position peaked at $5.24M in Q1 2026. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • State Street held 1,068,295 shares of Protara Therapeutics worth $4.08M as of Q2 2026.
  • State Street bought 63,153 Protara Therapeutics shares in Q2 2026, an estimated $300K.
  • Protara Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3104 holding.
  • State Street first reported a position in Protara Therapeutics in Q2 2015 and has held it in 29 quarters since.
  • State Street's Protara Therapeutics position peaked at $5.24M in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.